
    
      This study will consists of 3 dose cohorts with 2-7 participants in each of the three
      ascending dose cohorts. Initially 2 participants will be dosed in Cohort 1, followed by
      dosing of up to 5 additional participants if the cohort is expanded. Participants in cohort 2
      and 3 will receive 2-fold or 3-fold dose escalation to their respective preceding cohort
      doses if required.
    
  